ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
75 hedge funds and large institutions have $297M invested in ESSA Pharma in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 24 increasing their positions, 19 reducing their positions, and 23 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 19
0.11% more ownership
Funds ownership: 84.42% → 84.52% (+0.11%)
6% less funds holding
Funds holding: 80 → 75 (-5)
17% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 23
70% less capital invested
Capital invested by funds: $976M → $297M (-$679M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$40.9M |
| 2 |
Janus Henderson Group
London,
|
+$23.2M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$15.9M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$10.9M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$10M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$17.9M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$10.4M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$9.96M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$9.48M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$8.32M |
EPIX Hedge Fund Activity: Q3 2021 in Review
75 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q3 2021, worth a combined $297M — down 70% from $976M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of EPIX and 19 opened new positions — a net loss of 4 holders — while 19 trimmed existing stakes and 24 added.
The largest buyer was Bellevue Group, adding an estimated $40.9M. The largest seller was VR Adviser, exiting entirely with an estimated $17.9M sold.
- 75 institutional investors held ESSA Pharma (EPIX) as of Q3 2021, down from 80 in Q2 2021.
- Funds reported $297M of ESSA Pharma stock for Q3 2021, down 70% quarter-over-quarter.
- 19 funds opened new ESSA Pharma positions in Q3 2021 and 23 closed out, a net change of -4 holders.
- The largest ESSA Pharma buyer in Q3 2021 was Bellevue Group, an estimated $40.9M added.
- The largest ESSA Pharma seller in Q3 2021 was VR Adviser, an estimated $17.9M sold.
Based on aggregated 13F filings for Q3 2021.